Dr. Fox is an experienced entrepreneur and scientist. She was founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH.
Dr. Harris is a Principal of Middleburg Consultants, Inc., a pharmaceutical consulting firm. His experience in drug development spans two decades. He previously served as Chief Medical Officer of Napo Pharmaceuticals and Ocera Therapeutics. He was appointed Interim Chief Medical Officer of Tranzyme Pharmaceuticals in 2011. He has managed multicenter trials in gastrointestinal disease indications, including orphan disease indications, in North America, Europe, Australia, and Asia. He is concurrently Professor of Medicine in the Division of Gastroenterology at Georgetown University School of Medicine, where he maintains an academic medical practice. Dr. Harris is a magna cum laude graduate of Harvard College and Harvard Medical School. He undertook his post-graduate medical training at Johns Hopkins Hospital and Yale University School of Medicine and holds an M.S. in population health and administrative medicine from the University of Wisconsin Schools of Medicine. He is also a Fellow of the American College of Physicians and American Gastroenterological Association and serves on the scientific advisory panel for the Institute for One World Health, a non-profit organization dedicated to the prevention and treatment of pediatric diarrhea in third world nations. He is a recipient of the CCFA Premier Physician Award. He currently serves as an ad hoc member of the FDA GI Division Advisory Committee.
Dr. Hartman is a scientist and senior executive with over twenty years of experience successfully leading pharmaceutical research and development in multiple therapeutic areas. Before joining Avaxia, she was employed by AstraZeneca Pharmaceuticals as Vice President of Projects for Infectious Diseases in Innovative Medicines. Dr. Hartman previously held a variety of senior positions at AstraZeneca including Vice President of Respiratory & Inflammation Research and Vice President of Lead Generation DECS, a global science and technology group supporting early stage projects across all disease areas. Dr. Hartman began her career in the pharmaceutical industry at Hoffmann-La Roche in Basel, Switzerland, spending seven years in the Neuroscience Department before joining the Metabolic Disease Group in Nutley, NJ. Dr. Hartman received her A.B. in Molecular Biology from Princeton University and Ph.D. in Cellular and Molecular Physiology from Yale University.
Mr. Rivard is a business development and legal professional with over 20 years of experience in the biotechnology industry in both early stage and publicly traded companies, including 15 years in senior management. Previously, he served as Vice President, Corporate Development, at VaxDesign Corporation; Vice President, Corporate Development, at Galenea Corp.; Vice President, Business Development, at Synta Corporation; and Vice President, Strategic Development, at ArQule, Inc. where he also served as Vice President, Legal, and General Counsel. Mr. Rivard career has also included positions of Associate Counsel, Intellectual Property at the University of Massachusetts and as Corporate Attorney at Palmer and Dodge. Mr. Rivard earned a Juris Doctor degree at UCLA School of Law and an A.B. in biochemistry at Bowdoin College.
Mr. Sarney is an accomplished finance and accounting professional with over 15 years of experience in the biotechnology industry in both early-stage and publicly traded companies. Prior to joining Avaxia, he worked as a consultant from 2009 to 2013 at various biotechnology and medical device companies in interim VP of Finance and Controller roles. Prior to working as a consultant, Mr. Sarney was the Corporate Controller and Principal Accounting Officer of Nitromed, Inc., a publicly traded cardiovascular-focused pharmaceutical company. During his time at Nitromed, Mr. Sarney was responsible for SEC reporting, financial planning, risk management, treasury, the initiation of the company's Sarbanes-Oxley compliance efforts, and financial and accounting support for the launch of the company’s first product, BiDil. During his career, he has also held the position of audit supervisor within the technology assurance group of PricewaterhouseCoopers LLP. Mr. Sarney earned a B.S. in business management from the University of Hartford, an M.B.A. from Boston University and an M.A. in accounting from Suffolk University. Mr. Sarney is a certified public accountant in the state of Massachusetts.
Dr. Schauer is an executive level leader and scientist with over 25 years of experience in the development and manufacture of biologics. Most recently, he held the position of VP of Process Sciences at Inspiration Biopharmaceuticals. His past positions in the pharmaceuticals business include Senior Director Global Biologics at Hospira, Director of Manufacturing Sciences at Biogen Idec, and project management positions at EMD Pharmaceuticals and Biogen Idec. He also directed Technology and Product Development Groups at Millipore Corp. He began his career at Genetics Institute (now part of Pfizer). Dr. Schauer received his B.S. in Biochemistry and Biology and Ph.D. in Anaerobic Microbiology from Virginia Polytechnic Institute and received post-doctoral training at the University of Georgia.